This product is a prodrug of acyclovir. It is rapidly absorbed after oral administration and quickly converted into acyclovir in the body. Its antiviral effect is exerted by acyclovir. After acyclovir enters the herpes infected cells, it competes with deoxynucleoside for viral thymidine kinase or cell kinase. The drug is phosphorylated into activated acyclosine triphosphate, which competes with deoxyguanine triphosphate for viral DNA polymerase as a substrate for viral replication, thereby inhibiting viral DNA synthesis and showing antiviral effect. The antiviral activity of this product in vivo is better than that of acyclovir, and the therapeutic index for herpes simplex virus type I and type II is 42.91% and 30.13% higher than that of acyclovir, respectively. It also has a high efficacy against varicella zoster virus.

Zolmitriptan is a selective 5-HTIB/ID receptor agonist that stimulates 5-HTIB/ID receptors on intracranial blood vessels (including arteriovenous anastomoses) and sympathetic nerves of the trigeminal nervous system, causing intracranial vasoconstriction and inhibiting the release of pro-inflammatory neuropeptides.

Zolmitriptan is a selective 5-HT1B/1D receptor agonist. It stimulates 5-HT1B/1D receptors on intracranial blood vessels (including arteriovenous anastomoses) and sympathetic nerves of the trigeminal nervous system, causing intracranial vasoconstriction and inhibiting the release of pro-inflammatory neuropeptides. It is used to treat headaches with or without aura in adults.

Not described in detail

No specific pharmacological effects mentioned